Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Study on the Effectiveness of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called ABX464 for treating individuals with ulcerative colitis, a condition that causes inflammation and sores in the colon. The study aims to evaluate how effective and safe ABX464 is when taken once daily by people who have moderate to severe symptoms of this disease. Participants in the trial will receive either ABX464 or a placebo, which is a substance with no active medication, to compare the outcomes.

The trial will last for a period of eight weeks. During this time, participants will take the medication in the form of a hard capsule by mouth. The study will monitor the participants' health and symptoms to see if there is an improvement in their condition. The main goal is to see how many participants achieve clinical remission, which means their symptoms significantly improve or disappear. Additionally, the study will look at other factors such as endoscopic improvement, which involves examining the inside of the colon to check for healing, and any changes in symptoms or side effects experienced by the participants.

Throughout the study, the safety of the participants will be closely monitored, including any adverse events or side effects that may occur. The trial will also assess any significant changes in laboratory tests, vital signs, and heart function. The results of this study will help determine the potential benefits and risks of using ABX464 as a treatment option for people with ulcerative colitis.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be required to sign a written informed consent form. This form confirms that you understand the study and agree to participate.

    If you are under 18, additional consent from a guardian may be required, depending on local regulations.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm your eligibility. This includes verifying your diagnosis of ulcerative colitis and ensuring you meet the study criteria.

    Your medical history and current health status will be reviewed, and you may undergo tests such as endoscopy and histology.

  3. Step 3

    Treatment assignment

    You will be randomly assigned to receive either the study medication ABX464 or a placebo. A placebo is a substance with no active medication, used for comparison.

    The study is double-blind, meaning neither you nor the study team will know which treatment you are receiving.

  4. Step 4

    Medication administration

    If assigned to the ABX464 group, you will take a hard capsule orally once daily. The dosage will be either 25 mg or 50 mg, as determined by the study protocol.

    The treatment period lasts for 8 weeks, during which you will continue taking the medication daily.

  5. Step 5

    Regular monitoring

    Throughout the study, you will attend regular visits to monitor your health and response to the treatment.

    These visits may include physical examinations, laboratory tests, and questionnaires about your symptoms and overall well-being.

  6. Step 6

    End of treatment evaluation

    At the end of the 8-week treatment period, a final evaluation will be conducted to assess the effects of the treatment.

    This evaluation will include a review of your symptoms, any side effects experienced, and the results of any tests performed.

Who can join the trial?

8 criteria

  • Men or women who are at least 16 years old. If you are under 18, you must weigh at least 40 kg (about 88 pounds) and meet the definition of Tanner Stage 5, which means you have reached full physical maturity.
  • You must understand and sign a written consent form before any study procedures begin. If you are under the legal age, your country's consent requirements must also be met.
  • You must have a documented diagnosis of ulcerative colitis (UC) for more than 90 days before starting the study. This diagnosis should be confirmed by a procedure called endoscopy and a tissue examination called histology.
  • You must have active disease, which is measured by a modified Mayo score (MMS) of 5 or more, with a rectal bleeding subscore (RBS) of at least 1, and an endoscopy subscore (MES) of 2 or 3. These scores will be confirmed by a central reader.
  • You must have had an inadequate response, meaning the treatment did not work well enough, or you could not tolerate at least one of the following treatments: corticosteroids, immunosuppressants, biologic therapies, S1P receptor modulators, JAK inhibitors, or any new drugs approved during the study. Note that failure to respond only to 5-ASA is not accepted.
  • If you are a woman who can become pregnant or a man with a partner who can become pregnant, you must agree to use highly effective birth control methods as described in the study protocol.
  • You must be able and willing to attend study visits and follow the study procedures as outlined in the protocol.
  • You should have health insurance if it is required by the country or state where the study is taking place.

Who cannot join the trial?

10 criteria

  • Patients with any other significant health condition that might interfere with the study.
  • Patients who have had a recent infection that required treatment with antibiotics.
  • Patients who have a history of cancer, except for certain types of skin cancer that have been treated.
  • Patients who have a history of severe allergic reactions.
  • Patients who are currently pregnant or breastfeeding.
  • Patients who have participated in another clinical trial within the last 30 days.
  • Patients who have a history of substance abuse or alcohol abuse.
  • Patients who have a known infection with HIV, hepatitis B, or hepatitis C.
  • Patients who have had a major surgery within the last 6 months.
  • Patients who are unable to comply with the study procedures.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

ABX464 is a medication being studied for its potential to help people with ulcerative colitis, which is a condition that causes inflammation and sores in the colon. This medication is taken once a day and is being tested to see if it can help reduce the symptoms of ulcerative colitis and bring about clinical remission, meaning the symptoms are reduced or disappear. The study is comparing the effects of ABX464 to a placebo to determine how effective it is in treating this condition.

What is already known about the treatment

ABX464 – ABX464 is administered orally in the form of a once-daily pill. It is currently being studied in clinical trials as a potential treatment for moderately to severely active ulcerative colitis, a condition that causes inflammation and sores in the digestive tract. The main goal of the trials is to determine if ABX464 can help patients achieve clinical remission, meaning a reduction or disappearance of symptoms. At the molecular level, ABX464 works by modulating the immune response, which may help reduce inflammation in the colon. It is classified as an anti-inflammatory agent in pharmacology.

Investigated diseases

Ulcerative Colitis – Ulcerative colitis is a chronic inflammatory condition affecting the colon and rectum. It is characterized by continuous inflammation of the innermost lining of the large intestine, leading to the formation of ulcers. The disease typically begins in the rectum and may extend to involve the entire colon. Symptoms often include abdominal pain, diarrhea, and rectal bleeding. The inflammation can cause frequent and urgent bowel movements. Over time, the condition can lead to complications such as severe bleeding or colon damage.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2022-500536-11-00Protocol codeABX464-106Estimated enrolment547 patientsSponsorAbivax

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).